Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi®) Across Multiple Indications (EASE PAIN) | Synapse
April 13, 2026Open Access
Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi®) Across Multiple Indications (EASE PAIN)
Puntos clave
Assess injection site pain and medication adherence when transitioning between high and low volume adalimumab formulations.
Conducted a clinical trial with patients transitioning to AVT02 (Simlandi®) formulation.
Evaluated pain levels at injection sites during therapy.
Monitored medication adherence throughout the transition process.
Identified changes in injection site pain metrics during the transition.
Noted adherence rates following the switch to the low volume formulation.
Resumen
This trial is registered with ClinicalTrials.gov: NCT05913817.